Metastatic androgen pathway modulation-naïve or -sensitive prostate cancer was previously referred to as metastatic hormone-sensitive prostate cancer.

Credit: Bayer. Two phase 3 trials supported the approval of gadoquatrane, a novel macrocyclic GBCA for imaging CNS and non-CNS pathologies. The novel macrocyclic contrast agent delivers high-quality ...

A new extended maintenance regimen for Ebglyss has been approved for eligible patients with moderate to severe atopic dermatitis.

Phase 3 ISLEND-1 and ISLEND-2 trials met primary endpoints at week 48, showing a novel, once-weekly oral single-tablet regimen is noninferior to daily B/F/TAF or standard ART.

The group said the move was spurred by its commitment to evidence-based medicine amid a landscape of conflicting public health information.

Bemotrizinol is a newly approved over-the-counter sunscreen active ingredient that offers broad-spectrum protection with low systemic absorption.

The FDA linked 12 severe kidney complications to alli between 2007 and 2023, resulting in 8 hospitalizations and 5 patients requiring dialysis. The Food and Drug Administration (FDA) has updated the ...

Sanofi is stopping the phase 3 MOBILIZE clinical trial evaluating riliprubart in adult patients with chronic inflammatory demyelinating polyneuropathy who are refractory to standard therapies.

Findings showed navacaprant did not significantly improve MADRS total scores compared with placebo in either KOASTAL-2 (P =.813) or KOASTAL-3 (P =.480). Topline data were announced from two phase 3 ...

For more than one drink per occasion, higher consumption was associated with progressively increased risks for breast cancer, cardiovascular disease, and injury. HealthDay News — Two drinks per day is ...

Following a successful appeal of a December 2025 CRL, the FDA concluded that Outlook Therapeutics' existing data provided substantial evidence, eliminating the need for new clinical trials.